Federal Capture Intelligence

Top HHS pharmaceutical preparation manufacturing contractors (NAICS 325412)

Contract actions: October 1, 2021 – September 10, 2026 Updated September 11, 2026 Department of Health and Human Services agency guide NAICS 325412 · Pharmaceutical Preparation Manufacturing
Latest 12 months
$882.0M
Net obligations · Down $404.0M vs. $1.3B preceding
Prime contractors
60
With positive obligations in the latest 12 months

Research the HHS federal contracting market for pharmaceutical preparation manufacturing under NAICS 325412. Compare top federal contractors and market share, reported contract obligations and spending trends, funding-office attribution, recent award activity, contract types, competition, and procurement methods, observed contract vehicle usage, and potential recompete research leads.

Contract obligation trends for Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services

Federal records show $5.8B in net obligations across 1,157 awards in Pharmaceutical Preparation Manufacturing at the Department of Health and Human Services from Oct 1, 2021 through Sep 10, 2026. This market accounts for 4.0% of $145.5B in agency-wide net prime contract obligations over the period shown. Latest 12-month net obligations decreased 31.4% from $1.3B to $882.0M. 11 prime contractors accounted for at least 80% of positive obligations in that latest period.

Fiscal-year activity

FY26 is year-to-date through Sep 10, 2026; earlier years show complete fiscal-year totals.

FY26 year-to-date: $612.1M versus $847.2M through the same date in FY25 (−27.7%).
Net obligations · complete fiscal yearNet obligations · FY26 YTDContract actions
View fiscal-year data table
Fiscal yearNet obligationsContract actionsCoverage
FY2022$2.0B493Complete
FY2023$1.1B492Complete
FY2024$913.1M418Complete
FY2025$1.1B360Complete
FY2026$612.1M261YTD through Sep 10, 2026

Market at a glance

All reported prime contract awards
All-period net obligations
$5.8B
1,157 awards · 206 prime contractors
Latest 12-month movement
−31.4%
$882.0M vs. $1.3B
Leading eight prime share
70.7%
Share held by the eight leading prime contractors in the latest 12 months
View agency share, denominators, and set-aside reporting
Agency context
4.0% of $145.5B in agency-wide net obligations.
Set-aside share when reported
8.1% of 506 awards with reported set-aside status.
Set-aside reporting
41 set aside · 465 no set-aside · 651 not reported

What changed in the last 12 months?

Sep 11, 2025–Sep 10, 2026, compared with Sep 11, 2024–Sep 10, 2025.

Buyer demand

Reported obligations through BARDA - ASPR / DAAPPO / BARDA DCMA decreased
$385.9M→$132.2M−$253.7M
Latest-period activity spans 10 awards across 9 prime contractors.
Reported obligations through ASPR/DAAPPO/ORM HQ increased
$1.1M→$114.1M+$112.9M
Latest-period activity spans 4 awards across 2 prime contractors.

Competitive shifts

ALVOGEN, INC. had no reported activity in the latest 12 months
$284.8M→$0No latest-period activity
It previously ranked #1 by positive obligations, based on 4 reported actions.
GLAXOSMITHKLINE, LLC climbed the most in the contractor rankings
#52→#13Up 39 places
The contractor accounts for 2.9% of positive obligations across 7 reported actions.
RAFA LABORATORIES LTD was the largest newly observed contractor
$33.4MLatest 12-month obligations
First observed in this market on Sep 30, 2025, the contractor now ranks #11 by positive obligations across 2 reported actions.

Award activity

BAVARIAN NORDIC A/S received an unusually large obligation action
$97.0MMay 11, 2026 action
Reported under PIID HHSO100201700019C by BARDA - ASPR / DAAPPO / BARDA DCMA. Award net obligations after the action: $1.3B.
View supporting award
View 5 additional material changes

Competitive shifts

MCKESSON CORPORATION had the largest decline in reported obligations
$190.2M→$88.6M−$101.7M
The contractor now ranks #4 by positive obligations and accounts for 9.6% of positive obligations, based on 58 reported actions.
PHLOW CORP. gained the most market share
4.5%→12.3%+7.8 percentage points
The contractor now ranks #2 by positive obligations, based on 19 reported actions.
CHARTWELL RX LLC recorded the largest net deobligation
$114.8M→−$40.6M−$155.4M
The contractor now is unranked by positive obligations, based on 5 reported actions.
ELUSYS THERAPEUTICS INC lost the most market share
3.4%→0.0%−3.4 percentage points
The contractor now ranks outside the ranking by positive obligations, based on 3 reported actions.

Market structure

Top-five contractor share decreased
58.7%→52.7%−6.0 percentage points
Contractors outside the top five now account for 47.3% of positive obligations.
How these findings are calculated

Findings are selected from matched-period changes in obligations, share, rank, funding offices, concentration, reported set-asides, material award actions, and agency-peer outliers. Related signals are combined, and only material evidence-backed changes are shown. Review the full methodology.

Federal contract obligations by funding office

See how positive obligations were attributed across funding offices in the 12 months ending Sep 10, 2026.

45.3% of positive obligations were attributed to ASPR/ORM-SNS. That represents $411.1M, down $55.8M from the preceding 12 months.

Latest 12-month share of positive obligations; the gray segment represents all other reported offices.

  1. ASPR/ORM-SNS45.3% · $411.1M · down $55.8M
  2. BARDA - ASPR / DAAPPO / BARDA DCMA14.6% · $132.2M · down $253.7M
  3. INDIAN HEALTH SERVICE12.7% · $115.1M · up $82.4M
  4. ASPR/DAAPPO/ORM HQ12.6% · $114.1M · up $112.9M
  5. NATIONAL INSTITUTES OF HEALTH - CC7.4% · $66.8M · down $32.3M
  6. All other reported offices7.5% of positive obligations
View reported office rankings, comparisons, and evidence

USAspending assigns each award to a funding office. That office may differ from the requiring activity, program office, contracting office, individual buyer, or actual customer.

  1. Reported funding office

    ASPR/ORM-SNS

    #1Rank unchanged

    Latest 12 months

    $411.1M

    45.3% of positive obligations

    Versus preceding 12 months

    −$55.8M

    19 active prime contractors · 22 awards

    View office comparison and evidence

    Reported obligations decreased 12.0% from $466.9M to $411.1M. The office’s share of positive obligations moved from 36.3% to 45.3%, a change of +9.0 percentage points.

    The latest period contains 39 actions across 22 awards and 7 newly active prime contractors. The preceding period contained 19 active prime contractors and 26 awards.

  2. Reported funding office

    BARDA - ASPR / DAAPPO / BARDA DCMA

    #2Rank unchanged

    Latest 12 months

    $132.2M

    14.6% of positive obligations

    Versus preceding 12 months

    −$253.7M

    9 active prime contractors · 10 awards

    View office comparison and evidence

    Reported obligations decreased 65.7% from $385.9M to $132.2M. The office’s share of positive obligations moved from 30.0% to 14.6%, a change of −15.4 percentage points.

    The latest period contains 10 actions across 10 awards and 5 newly active prime contractors. The preceding period contained 9 active prime contractors and 9 awards.

    Leading award-level changes

  3. Reported funding office

    INDIAN HEALTH SERVICE

    #3Up 5 from #8

    Latest 12 months

    $115.1M

    12.7% of positive obligations

    Versus preceding 12 months

    +$82.4M

    5 active prime contractors · 33 awards

    View office comparison and evidence

    Reported obligations increased 251.9% from $32.7M to $115.1M. The office’s share of positive obligations moved from 2.5% to 12.7%, a change of +10.1 percentage points.

    The latest period contains 34 actions across 33 awards and 1 newly active prime contractor. The preceding period contained 6 active prime contractors and 24 awards.

  4. Reported funding office

    ASPR/DAAPPO/ORM HQ

    #4Up 9 from #13

    Latest 12 months

    $114.1M

    12.6% of positive obligations

    Versus preceding 12 months

    +$112.9M

    2 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations increased 9889.6% from $1.1M to $114.1M. The office’s share of positive obligations moved from 0.090% to 12.6%, a change of +12.5 percentage points.

    The latest period contains 22 actions across 4 awards. The preceding period contained 2 active prime contractors and 8 awards.

    Leading award-level changes

  5. Reported funding office

    NATIONAL INSTITUTES OF HEALTH - CC

    #5Down 2 from #3

    Latest 12 months

    $66.8M

    7.4% of positive obligations

    Versus preceding 12 months

    −$32.3M

    23 active prime contractors · 33 awards

    View office comparison and evidence

    Reported obligations decreased 32.6% from $99.1M to $66.8M. The office’s share of positive obligations moved from 7.7% to 7.4%, a change of −0.3 percentage points.

    The latest period contains 41 actions across 33 awards and 12 newly active prime contractors. The preceding period contained 21 active prime contractors and 64 awards.

  6. Reported funding office

    CDC OFFICE OF ACQUISITION SERVICES

    #6Rank unchanged

    Latest 12 months

    $51.3M

    5.7% of positive obligations

    Versus preceding 12 months

    −$10.3M

    4 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations decreased 16.8% from $61.6M to $51.3M. The office’s share of positive obligations moved from 4.8% to 5.7%, a change of +0.9 percentage points.

    The latest period contains 14 actions across 4 awards and 2 newly active prime contractors. The preceding period contained 4 active prime contractors and 4 awards.

  7. Reported funding office

    PHOENIX AREA INDIAN HEALTH SVC

    #7Rank unchanged

    Latest 12 months

    $8.9M

    0.98% of positive obligations

    Versus preceding 12 months

    −$49.0M

    6 active prime contractors · 12 awards

    View office comparison and evidence

    Reported obligations decreased 84.7% from $57.8M to $8.9M. The office’s share of positive obligations moved from 4.5% to 0.98%, a change of −3.5 percentage points.

    The latest period contains 17 actions across 12 awards. The preceding period contained 6 active prime contractors and 34 awards.

  8. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NINDS

    #8Up 2 from #10

    Latest 12 months

    $2.7M

    0.30% of positive obligations

    Versus preceding 12 months

    +$221K

    2 active prime contractors · 4 awards

    View office comparison and evidence

    Reported obligations increased 8.8% from $2.5M to $2.7M. The office’s share of positive obligations moved from 0.19% to 0.30%, a change of +0.1 percentage points.

    The latest period contains 5 actions across 4 awards and 1 newly active prime contractor. The preceding period contained 1 active prime contractor and 3 awards.

  9. Reported funding office

    OMAS STRATEGIC BUYING CENTER - HHS MISSION

    #9New to the positive-obligation ranking

    Latest 12 months

    $1.3M

    0.15% of positive obligations

    Versus preceding 12 months

    +$1.3M

    2 active prime contractors · 2 awards

    View office comparison and evidence

    Reported obligations rose from $0 to $1.3M. The office’s share of positive obligations moved from 0% to 0.15%, a change of +0.1 percentage points.

    The latest period contains 3 actions across 2 awards and 2 newly active prime contractors. The preceding period contained 0 active prime contractors and 0 awards.

  10. Reported funding office

    NIH NCI

    #10Up 5 from #15

    Latest 12 months

    $1.0M

    0.11% of positive obligations

    Versus preceding 12 months

    +$403K

    5 active prime contractors · 8 awards

    View office comparison and evidence

    Reported obligations increased 67.5% from $597K to $1.0M. The office’s share of positive obligations moved from 0.050% to 0.11%, a change of +0.1 percentage points.

    The latest period contains 9 actions across 8 awards and 4 newly active prime contractors. The preceding period contained 4 active prime contractors and 13 awards.

  11. Reported funding office

    NATIONAL INSTITUTES OF HEALTH NCATS

    #11Up 5 from #16

    Latest 12 months

    $740K

    0.080% of positive obligations

    Versus preceding 12 months

    +$297K

    1 active prime contractor · 1 award

    View office comparison and evidence

    Reported obligations increased 67.0% from $443K to $740K. The office’s share of positive obligations moved from 0.030% to 0.080%, a change of +0.1 percentage points.

    The latest period contains 2 actions across 1 award and 1 newly active prime contractor. The preceding period contained 6 active prime contractors and 7 awards.

  12. Reported funding office

    INDUSTRIAL BASED MANUFACTURING AND SUPPLY CHAIN (IBMSC)

    No positive-obligation rank

    Latest 12 months

    $0

    0% of positive obligations

    Versus preceding 12 months

    −$73.2M

    0 active prime contractors · 0 awards

    View office comparison and evidence

    Reported obligations decreased 100.0% from $73.2M to $0. The office’s share of positive obligations moved from 5.7% to 0%, a change of −5.7 percentage points.

    The latest period contains 0 actions across 0 awards. The preceding period contained 2 active prime contractors and 2 awards.

  13. Reported funding office

    NAVAJO AREA INDIAN HEALTH SVC

    No positive-obligation rank

    Latest 12 months

    −$24.9M

    0% of positive obligations

    Versus preceding 12 months

    −$120.4M

    8 active prime contractors · 29 awards

    View office comparison and evidence

    Reported obligations moved from $95.5M in net obligations to $24.9M in net deobligations. The office’s share of positive obligations moved from 7.4% to 0%, a change of −7.4 percentage points.

    The latest period contains 35 actions across 29 awards and 5 newly active prime contractors. The preceding period contained 7 active prime contractors and 47 awards.

Contract types, competition, and procurement methods

From Sep 11, 2025 through Sep 10, 2026, 107 awards had positive obligations totaling $951.9M. Only One Source was the leading reported procedure, accounting for 26.3% of positive obligations. Awards with a reported parent IDV accounted for 32.1%. Reported awards used contract vehicles such as VA FSS Schedule 65IB.

Leading award type
67.4%
Definitive Contract
Leading reported procedure
26.3%
Only One Source
Reported parent IDV
32.1%
of positive obligations had a reported parent IDV
Median reported offers
1
63 of 107 awards reported offers

Observed contract vehicles

Only exact reported parent-PIID matches are shown; missing parent IDs are not inferred.

Buying method changes

Compared with Sep 11, 2024–Sep 10, 2025. Based on 107 current awards and 146 preceding awards with positive net obligations.

Reported full-and-open obligation share
37.0%
Down from 58.1% in the preceding period
Parent-IDV obligation share
32.1%
Down from 46.7% in the preceding period
How to read these changes

Directional color and the Up or Down labels show historical movement only. Green does not mean favorable and red does not mean unfavorable; neither predicts a future procurement method.

Same-NAICS comparison

Compared with the NAICS 325412 peer median, parent-IDV obligation share is 66.0 percentage points lower, reported full-and-open obligation share is 19.4 percentage points lower, delivery-order obligation share is 65.9 percentage points lower, and median positive award obligations are 4575.9% higher.

MeasureThis marketPeer medianDifference
Parent-IDV obligation share32.1%98.2%-66.0 pts
Reported full-and-open obligation share37.0%56.4%-19.4 pts
Delivery-order obligation share32.0%98.0%-65.9 pts
Median positive award obligations$529K$11K+4575.9%
Peer cohort and comparison limits

The peer median gives each of the 3 eligible agency markets equal weight. The included agency markets are:

Agency mission, scale, and acquisition context can differ. Peer position does not establish market attractiveness or predict a future procurement method.

View buying-method details and data coverage

Award types

Reported valueAwardsPositive obligationsShare
Definitive Contract(D)17$641.7M67.4%
Delivery Order(C)58$304.7M32.0%
Purchase Order(B)26$4.3M0.45%
BPA Call(A)6$1.1M0.12%

Reported parent-award types

Reported valueAwardsPositive obligationsShare
FSS(C)11$174.0M18.3%
IDC(B)47$130.8M13.7%
BPA(E)6$1.1M0.12%
Not reported43$646.0M67.9%

Single- or multiple-award parent structure

Reported valueAwardsPositive obligationsShare
Multiple Award(M)15$176.9M18.6%
Single Award(S)49$128.9M13.6%
Not reported43$646.0M67.9%

Solicitation procedures

Reported valueAwardsPositive obligationsShare
Only One Source(SSS)8$250.2M26.3%
Negotiated Proposal/Quote(NP)38$230.6M24.2%
Sss(ONLY ONE SOURCE)3$205.9M21.6%
Subject to Multiple Award Fair Opportunity(MAFO)10$121.6M12.8%
Np(NEGOTIATED PROPOSAL/QUOTE)9$83.8M8.8%
Mafo(SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY)4$55.1M5.8%
Other reported values35$4.6M0.48%

Extent competed

Reported valueAwardsPositive obligationsShare
Full and Open Competition(A)47$351.8M37.0%
Not Competed(C)8$250.2M26.3%
C(NOT COMPETED)3$205.9M21.6%
A(FULL AND OPEN COMPETITION)11$137.6M14.5%
Competed Under SAP(F)20$1.7M0.18%
Not Competed Under SAP(G)8$1.6M0.17%
Other reported values10$3.0M0.31%

Fair-opportunity and limited-source reporting

Reported valueAwardsPositive obligationsShare
Only One Source - Other(ONE)6$104.3M11.0%
Fair Opportunity Given(FAIR)7$42.4M4.5%
Urgency(URG)1$30.0M3.1%
Not reported93$775.1M81.4%

Other-than-full-and-open reasons

Reported valueAwardsPositive obligationsShare
Only One Source-Other (FAR 6.302-1 Other)(ONE)9$288.7M30.3%
Mobilization, Essential R&d (FAR 6.302-3)(MES)1$113.6M11.9%
Unique Source (FAR 6.302-1(B)(1))(UNQ)1$53.7M5.7%
SAP Non-Competition (FAR 13)(SP2)8$1.8M0.19%
Authorized by Statute (FAR 6.302-5(A)(2)(I))(OTH)1$86K0.010%
Less Than or Equal to the Micro-Purchase Threshold(MPT)1$3K0%
Not reported86$493.9M51.9%

Contract pricing types

Reported valueAwardsPositive obligationsShare
Firm Fixed Price(J)83$604.3M63.5%
J(FIRM FIXED PRICE)18$230.3M24.2%
U(COST PLUS FIXED FEE)4$115.5M12.1%
Cost Plus Fixed Fee(U)2$1.7M0.18%

Product or Service Codes

Reported valueAwardsPositive obligationsShare
Drugs and Biologicals(6505)82$680.7M71.5%
R&d- Medical: Biomedical (Commercialized)(AN17)1$113.6M11.9%
Chemical and Pharmaceutical Products Manufacturing Machinery(3650)6$51.8M5.4%
Support- Administrative: Mailing/Distribution(R604)1$51.1M5.4%
Medical and Surgical Instruments, Equipment, and Supplies(6515)4$50.2M5.3%
Health R&d Services; Health Care Services; Basic Research(AN11)1$1.4M0.14%
Other reported values12$3.1M0.32%

Awarding subagencies

Reported valueAwardsPositive obligationsShare
Office of Assistant Secretary for Preparedness and Response(7505)23$699.0M73.4%
Indian Health Service(7527)43$126.3M13.3%
National Institutes of Health(7529)30$72.3M7.6%
Centers for Disease Control and Prevention(7523)4$51.3M5.4%
Office of the Assistant Secretary for Financial Resources(7571)2$1.3M0.14%
Departmental Offices(1406)1$740K0.080%
Other reported values4$922K0.097%

Awarding offices

Reported valueAwardsPositive obligationsShare
Aspr/Orm-Sns(75A503)18$487.9M51.3%
Indian Health Service(75H711)23$115.5M12.1%
Aspr/Daappo/Orm Hq(75A502)4$114.1M12.0%
Barda - Aspr / Daappo / Barda Dcma(75A501)1$97.0M10.2%
National Institutes of Health Olao(75N980)12$68.0M7.2%
Cdc Office of Acquisition Services(75D301)4$51.3M5.4%
Other reported values45$18.1M1.9%

Reported parent IDVs

Reported valueAwardsPositive obligationsShare
36W79720D0001(3600)30$115.4M12.1%
36F79723D0171(3600)1$50.0M5.3%
36F79723D0219(3600)1$37.5M3.9%
36F79723D0101(3600)1$30.0M3.1%
36F79724D0107(3600)1$16.6M1.8%
V797D70258(3600)1$16.2M1.7%
36F79720D0237(3600)1$15.1M1.6%
36F79725D0145(3600)1$7.9M0.83%
Other reported values27$17.2M1.8%
Not reported43$646.0M67.9%

Exact vehicle-match evidence

Reported award data linked 3 awards to a specific catalog vehicle.

Offers, award size, and timing

Median reported offers
1 median
63 reported · 44 not reported
Positive award obligations
$529K median
$100K–$7.6M middle 50%
Reported performance period
364 days (~12 months) median
107 reported · 0 not reported

Calculations group latest-period actions by award, retain awards with positive net obligations for share denominators, and use each award's latest reported USAspending procurement fields as of Sep 10, 2026. Blank competition, pricing, PSC, or parent-IDV values remain not reported; they are not inferred. Offer counts must be positive and below the FPDS 999 placeholder. Awarding organizations can differ from the funding agency that defines this page.

Top federal contractors

Latest 12-month market share, concentration, and complete prime contractor rankings across the period shown.

Prime contractor concentration
11 of 60prime contractors account for at least 80% of positive obligations in the last 12 months
Largest prime contractor
12.8%of positive obligations in the last 12 months
Leading four prime contractors
45.2%of positive obligations in the last 12 months
Leading eight prime contractors
70.7%of positive obligations in the last 12 months

Based on $924.2M in positive obligations during the 12 months ending Sep 10, 2026. Individual shares and movement appear in the searchable rankings below. Movement compares with Sep 11, 2024–Sep 10, 2025.

Last 12mo obligation volume: Highest positive obligations first; net deobligations follow by magnitude; contractors with no activity in the last 12 months follow by all-period obligations. Ranks use the complete contractor list and remain fixed when search narrows the results.

15 leading contractors
  1. #1

    Last 12mo obligations

    $118.3M

    12.8%

    Dollar movement

    +$4.0M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for EMERGENT BIOSOLUTIONS CANADA INC
    Obligations: prior → latest
    $114.3M → $118.3M
    +3.5%
    Share: prior → latest
    7.0% → 12.8%
    +5.7 percentage points
    All-period obligations
    $558.4M
    9.6% of all-period positive obligations · 2 awards
    Recorded activity
    Since Oct 22, 2021
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  2. #2

    Last 12mo obligations

    $113.6M

    12.3%

    Dollar movement

    +$40.5M

    vs. prior 12 months

    Last 12mo awards

    1 award

    19 actions

    Historical and award details for PHLOW CORP.
    Obligations: prior → latest
    $73.2M → $113.6M
    +55.3%
    Share: prior → latest
    4.5% → 12.3%
    +7.8 percentage points
    All-period obligations
    $342.4M
    5.9% of all-period positive obligations · 1 award
    Recorded activity
    Since Nov 16, 2021
    through Sep 2, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business11
    All-period set-aside types

    None reported.

  3. #3

    Last 12mo obligations

    $97.0M

    10.5%

    Dollar movement

    −$109.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for BAVARIAN NORDIC A/S
    Obligations: prior → latest
    $206.6M → $97.0M
    −53.1%
    Share: prior → latest
    12.7% → 10.5%
    −2.3 percentage points
    All-period obligations
    $882.1M
    15.2% of all-period positive obligations · 1 award
    Recorded activity
    Since May 17, 2022
    through May 11, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  4. #4

    Last 12mo obligations

    $88.6M

    9.6%

    Dollar movement

    −$101.7M

    vs. prior 12 months

    Last 12mo awards

    54 awards

    58 actions

    Historical and award details for MCKESSON CORPORATION
    Obligations: prior → latest
    $190.2M → $88.6M
    −53.4%
    Share: prior → latest
    11.7% → 9.6%
    −2.1 percentage points
    All-period obligations
    $691.4M
    11.9% of all-period positive obligations · 367 awards
    Recorded activity
    Since Oct 26, 2021
    through Sep 1, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside15
    Not reported5374
    Reported small business00
    All-period set-aside types

    None reported.

  5. #5

    Last 12mo obligations

    $69.6M

    7.5%

    Dollar movement

    +$19.5M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    3 actions

    Historical and award details for FRESENIUS KABI, LLC
    Obligations: prior → latest
    $50.0M → $69.6M
    +39.1%
    Share: prior → latest
    3.1% → 7.5%
    +4.5 percentage points
    All-period obligations
    $124.3M
    2.1% of all-period positive obligations · 3 awards
    Recorded activity
    Since Feb 28, 2023
    through Aug 31, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported10
    Reported small business00
    All-period set-aside types

    None reported.

  6. #6

    Last 12mo obligations

    $65.5M

    7.1%

    Dollar movement

    −$32.6M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    6 actions

    Historical and award details for DLA TROOP SUPPORT
    Obligations: prior → latest
    $98.1M → $65.5M
    −33.2%
    Share: prior → latest
    6.0% → 7.1%
    +1.0 percentage points
    All-period obligations
    $399.7M
    6.9% of all-period positive obligations · 10 awards
    Recorded activity
    Since Oct 18, 2021
    through Apr 17, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside22
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  7. #7

    Last 12mo obligations

    $51.1M

    5.5%

    Dollar movement

    −$10.4M

    vs. prior 12 months

    Last 12mo awards

    1 award

    10 actions

    Historical and award details for MCKESSON SPECIALTY DISTRIBUTION LLC
    Obligations: prior → latest
    $61.5M → $51.1M
    −17.0%
    Share: prior → latest
    3.8% → 5.5%
    +1.7 percentage points
    All-period obligations
    $579.2M
    9.9% of all-period positive obligations · 2 awards
    Recorded activity
    Since Aug 2, 2022
    through Jun 24, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside11
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  8. #8

    Last 12mo obligations

    $50.0M

    5.4%

    Dollar movement

    +$10.9M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for PARTNER THERAPEUTICS, INC.
    Obligations: prior → latest
    $39.1M → $50.0M
    +27.8%
    Share: prior → latest
    2.4% → 5.4%
    +3.0 percentage points
    All-period obligations
    $192.5M
    3.3% of all-period positive obligations · 3 awards
    Recorded activity
    Since Feb 15, 2022
    through Jun 10, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

  9. #9

    Last 12mo obligations

    $46.0M

    5.0%

    Dollar movement

    +$9.4M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    2 actions

    Historical and award details for MERIDIAN MEDICAL TECHNOLOGIES, LLC
    Obligations: prior → latest
    $36.6M → $46.0M
    +25.8%
    Share: prior → latest
    2.3% → 5.0%
    +2.7 percentage points
    All-period obligations
    $92.6M
    1.6% of all-period positive obligations · 3 awards
    Recorded activity
    Since Sep 22, 2023
    through Jan 5, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside10
    Reported no set-aside11
    Not reported00
    Reported small business10
    All-period set-aside types
    • 1 · Total small business
  10. #10

    Last 12mo obligations

    $37.5M

    4.1%

    Dollar movement

    +$367.4M

    vs. prior 12 months

    Last 12mo awards

    2 awards

    4 actions

    Historical and award details for GENENTECH USA, INC
    Obligations: prior → latest
    −$329.9M → $37.5M
    Not comparable
    Share: prior → latest
    0% → 4.1%
    +4.1 percentage points
    All-period obligations
    $164.6M
    2.8% of all-period positive obligations · 5 awards
    Recorded activity
    Since Sep 7, 2022
    through Aug 12, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported24
    Reported small business00
    All-period set-aside types

    None reported.

  11. #11

    Last 12mo obligations

    $33.4M

    3.6%

    Dollar movement

    +$33.4M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for RAFA LABORATORIES LTD
    Obligations: prior → latest
    $0 → $33.4M
    Not comparable
    Share: prior → latest
    0% → 3.6%
    +3.6 percentage points
    All-period obligations
    $33.4M
    0.57% of all-period positive obligations · 1 award
    Recorded activity
    Since Sep 30, 2025
    through Jul 29, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported00
    Reported small business00
    All-period set-aside types

    None reported.

  12. #12

    Last 12mo obligations

    $30.0M

    3.3%

    Dollar movement

    +$30.0M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for USANTIBIOTICS LLC
    Obligations: prior → latest
    $0 → $30.0M
    Not comparable
    Share: prior → latest
    0% → 3.3%
    +3.3 percentage points
    All-period obligations
    $30.0M
    0.52% of all-period positive obligations · 1 award
    Recorded activity
    Since May 27, 2026
    through May 27, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business10
    All-period set-aside types

    None reported.

  13. #13

    Last 12mo obligations

    $27.2M

    2.9%

    Dollar movement

    +$27.2M

    vs. prior 12 months

    Last 12mo awards

    5 awards

    7 actions

    Historical and award details for GLAXOSMITHKLINE, LLC
    Obligations: prior → latest
    $882 → $27.2M
    +3083047.4%
    Share: prior → latest
    0% → 2.9%
    +2.9 percentage points
    All-period obligations
    $45.6M
    0.78% of all-period positive obligations · 25 awards
    Recorded activity
    Since Oct 19, 2021
    through Aug 18, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside10
    Not reported41
    Reported small business00
    All-period set-aside types

    None reported.

  14. #14

    Last 12mo obligations

    $16.6M

    1.8%

    Dollar movement

    +$16.6M

    vs. prior 12 months

    Last 12mo awards

    1 award

    1 action

    Historical and award details for SAGENT PHARMACEUTICALS, INC
    Obligations: prior → latest
    $0 → $16.6M
    Not comparable
    Share: prior → latest
    0% → 1.8%
    +1.8 percentage points
    All-period obligations
    $64.4M
    1.1% of all-period positive obligations · 2 awards
    Recorded activity
    Since Aug 29, 2022
    through Sep 26, 2025

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported10
    Reported small business10
    All-period set-aside types

    None reported.

  15. #15

    Last 12mo obligations

    $16.2M

    1.8%

    Dollar movement

    +$16.2M

    vs. prior 12 months

    Last 12mo awards

    1 award

    2 actions

    Historical and award details for HEYLTEX CORPORATION
    Obligations: prior → latest
    $0 → $16.2M
    Not comparable
    Share: prior → latest
    0% → 1.8%
    +1.8 percentage points
    All-period obligations
    $23.3M
    0.40% of all-period positive obligations · 3 awards
    Recorded activity
    Since Aug 24, 2022
    through Aug 21, 2026

    Award reporting

    Latest and prior 12-month award reporting
    Reported award evidenceLatestPrior
    Reported set-aside00
    Reported no set-aside00
    Not reported11
    Reported small business11
    All-period set-aside types

    None reported.

Potential federal contract recompetes

Investigate potential recompetes surfaced by near-term end dates, award value, and recent contract changes.

BAVARIAN NORDIC A/S

BAVARIAN NORDIC MOD 21

$1.26B is obligated on an award with a reported potential end date of September 26, 2027.

Performance period

89.6%

As of Sep 10, 2026Potential end Sep 26, 2027

Current award value as a share of potential value

73.9%

$1.3B current$1.7B potential
Supporting data

Reported performance starts Sep 27, 2017.

No later potential end date is reported; current and potential end dates are both Sep 26, 2027.

$1.3B is obligated against $1.3B in current reported award value (100.0%).

Reported potential end dates: Sep 26, 2026 → Sep 26, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID HHSO100201700019C

PARTNER THERAPEUTICS, INC.

EXERCISE OPTIONAL ORDERING PERIOD 2 FOR LEUKINE 250MCG VIAL INJECTABLES

$133.5M is obligated on an award with a reported potential end date of March 29, 2027.

Performance period

84.4%

As of Sep 10, 2026Potential end Mar 29, 2027

Current award value as a share of potential value

100.0%

$133.5M current$133.5M potential
Supporting data

Reported performance starts Sep 26, 2023.

No later potential end date is reported; current and potential end dates are both Mar 29, 2027.

$133.5M is obligated against $133.5M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Sep 29, 2027 → Mar 29, 2027.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50323F80027

ALVOGEN, INC.

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.

$227.7M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

59.9%

As of Sep 10, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$227.7M current$227.7M potential
Supporting data

Reported performance starts Jun 30, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$227.7M is obligated against $227.7M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80013

BAXTER HEALTHCARE CORPORATION

PRALIDOXIME CHLORIDE (PROTOPAM)

$39.2M is obligated on an award with a reported potential end date of September 29, 2026.

Performance period

99.0%

As of Sep 10, 2026Potential end Sep 29, 2026

Current award value as a share of potential value

75.1%

$39.2M current$52.2M potential
Supporting data

Reported performance starts Sep 30, 2021.

Current performance is reported through Sep 29, 2025.

$39.2M is obligated against $39.2M in current reported award value (100.0%).

Reported potential end dates: Sep 29, 2026 → Dec 27, 2022 → Sep 29, 2024 → Sep 29, 2026.

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50121C00084

DLA TROOP SUPPORT

PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472]

$65.0M is obligated on an award with a reported potential end date of April 9, 2027.

Performance period

42.0%

As of Sep 10, 2026Potential end Apr 9, 2027

Current award value as a share of potential value

100.0%

$65.0M current$65.0M potential
Supporting data

Reported performance starts Apr 10, 2026.

No later potential end date is reported; current and potential end dates are both Apr 9, 2027.

$65.0M is obligated against $65.0M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75N98026C00026

EXELAN PHARMACEUTICALS INC

OSELTAMIVIR PHOSPHATE 30MG CAPSULES CHANGE NDC FROM NDC 47781-468-13 TO NDC: 76282-0702-45); 10 CT. CAPSULES PACKS.

$74.1M is obligated on an award with a reported potential end date of June 29, 2027.

Performance period

60.1%

As of Sep 10, 2026Potential end Jun 29, 2027

Current award value as a share of potential value

100.0%

$74.1M current$74.1M potential
Supporting data

Reported performance starts Jun 28, 2025.

No later potential end date is reported; current and potential end dates are both Jun 29, 2027.

$74.1M is obligated against $74.1M in current reported award value (100.0%).

Obligations are compared with current reported award value, not treated as a contract ceiling.

PIID 75A50325F80014

These are research leads, not confirmed recompetes. USAspending records through Sep 10, 2026; reported dates and values can change through later modifications.

Recent federal contract award activity

Recent contract actions with unusually large obligation changes or meaningful shifts in contractor and funding-office activity.

Modification

This action

+$53.9M

PHLOW CORP.

ASPR/DAAPPO/ORM HQ

THE PURPOSE OF THIS ACTION IS TO FUND THE REMAINING APIS FOR THE STRATEGIC RESERVE

Why it stands out

The contractor climbed 7 positions in this market.

It now ranks #2 by positive obligations over the latest 12 months.

Award net obligations
$696.7M
Share of 12-month positive obligations
5.8%
Supporting data
Prime contractor
#2 · 12.3% share
up 7 ranks · +7.8 percentage points · $40.5M net increase; action exceeded it by $13.4M
Funding office
#4 · 12.6% attributed share
up 9 ranks · +12.5 percentage points · $112.9M net increase; action accounted for 47.7%
Related:Funding office gainLargest share gain
PIID 75A50120C00092 · Mod P00027
Modification

This action

+$97.0M

BAVARIAN NORDIC A/S

BARDA - ASPR / DAAPPO / BARDA DCMA

BAVARIAN NORDIC MOD 21

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $97.0M while office-attributed obligations fell $253.7M overall.

Award net obligations
$1.3B
Share of 12-month positive obligations
10.5%
Supporting data
Prime contractor
#3 · 10.5% share
$109.6M net decline despite this positive action
Funding office
#2 · 14.6% attributed share
$253.7M net decline despite this positive action
Related:Unusually large action
PIID HHSO100201700019C · Mod P00021
Modification

This action

+$64.5M

EMERGENT BIOSOLUTIONS CANADA INC

ASPR/ORM-SNS

EO14042 BOTULISM ANTITOXIN

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $64.5M while office-attributed obligations fell $55.8M overall.

Award net obligations
$320.9M
Share of 12-month positive obligations
7.0%
Supporting data
Funding office
#1 · 45.3% attributed share
$55.8M net decline despite this positive action
PIID 75A50119C00075 · Mod P00015
Deobligation

This action

−$40.6M

CHARTWELL RX LLC

ASPR/ORM-SNS

THE PURPOSE OF THIS MODIFICATION IS TO DESCOPE AMOXICILLIN TRIHYDRATE 500 MG CLINS.

Why it stands out

This award recorded a material contraction.

The action removed $40.6M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$99.0M
Share of 12-month positive obligations
4.4%
Supporting data
Prime contractor
0% share
−7.1 percentage points · $155.4M net decline; action accounted for 26.1%
Related:Largest net deobligation
PIID 75A50322F80030 · Mod P00007
Modification

This action

+$51.0M

MCKESSON SPECIALTY DISTRIBUTION LLC

CDC OFFICE OF ACQUISITION SERVICES

CENTRALIZED VACCINE DISTRIBUTION

Why it stands out

This award grew while spending attributed to its office declined.

The modification added $51.0M while office-attributed obligations fell $10.3M overall.

Award net obligations
$203.9M
Share of 12-month positive obligations
5.5%
Supporting data
Prime contractor
#7 · 5.5% share
$10.4M net decline despite this positive action
Funding office
#6 · 5.7% attributed share
$10.3M net decline despite this positive action
PIID 75D30123C17978 · Mod P00012
Deobligation

This action

−$47.8M

ALTITUDE TECHNOLOGIES INC.

ASPR/ORM-SNS

PURPOSE OF MODIFICATION IS TO TERMINATE DELIVERY ORDER FOR AMOXICILLIN TRIHYDRATE 500 MG ORAL CAPSULES AT NO COST TO THE GOVERNMENT.

Why it stands out

This award recorded a material contraction.

The action removed $47.8M. A deobligation does not by itself show lower requirement demand.

Award net obligations
$0
Share of 12-month positive obligations
5.2%
Supporting data
Funding office
#1 · 45.3% attributed share
+9.0 percentage points · $55.8M net decline; action accounted for 85.7%
PIID 75A50325F80038 · Mod P00001
View recent award activity by date (10)
  1. ALCHEM LABORATORIES CORPORATIONDeobligation · PIID 75N91021F00001
    Action−$82K
    Award net obligations$2.7M
  2. RARE DISEASE THERAPEUTICS, INC.Modification · PIID 75H71226F80033
    Action+$36K
    Award net obligations$82K
  3. MCKESSON CORPORATIONDeobligation · PIID 75H71020P00260
    Action−$30K
    Award net obligations$0
  4. FRESENIUS KABI, LLCModification · PIID 75A50325C00004
    Action+$25.4M
    Award net obligations$111.7M
  5. MARATHON MEDICAL CORPORATIONBase award · PIID 75H71226F28004
    Action+$180K
    Award net obligations$180K
  6. CHAYMAA FAOUR LLCModification · PIID 75A50325C00014
    Action+$340K
    Award net obligations$494K
  7. MCKESSON CORPORATIONDeobligation · PIID 75H71022F80548
    Action−$192K
    Award net obligations$8K
  8. BAXTER HEALTHCARE CORPORATIONModification · PIID 75A50325C00013
    Action+$14.4M
    Award net obligations$18.8M
  9. MCKESSON CORPORATIONDeobligation · PIID 75H71020F81219
    Action−$1.2M
    Award net obligations$5.1M
  10. MCKESSON CORPORATIONDeobligation · PIID 75H71020F81222
    Action−$426K
    Award net obligations$1.0M

HHS pharmaceutical preparation manufacturing market FAQs

Answers based on reported federal contract data.

Who are the top HHS pharmaceutical preparation manufacturing contractors?

In the 12 months through September 10, 2026, EMERGENT BIOSOLUTIONS CANADA INC, PHLOW CORP., and BAVARIAN NORDIC A/S were the leading HHS pharmaceutical preparation manufacturing prime contractors by positive obligations.

  1. #1

    EMERGENT BIOSOLUTIONS CANADA INC

    $118,251,472 in positive obligations

  2. #2

    PHLOW CORP.

    $113,641,156 in positive obligations

  3. #3

    BAVARIAN NORDIC A/S

    $96,961,504 in positive obligations

Rankings use reported USAspending award data.

Did HHS contract obligations decrease in the pharmaceutical preparation manufacturing market?

Yes. Measured by net prime contract obligations, reported HHS activity in the pharmaceutical preparation manufacturing market decreased 31.4% from $1,285,943,822 in the preceding 12 months to $881,967,177 in the 12 months through September 10, 2026.

Latest 12 months
$881,967,177
Net prime contract obligations
Preceding 12 months
$1,285,943,822
Net prime contract obligations
Change
−31.4%
Between matched 12-month periods

Reported contract actions, not outlays or a forecast.

What recent HHS contract award activity was reported in the pharmaceutical preparation manufacturing market?

Recent HHS contract award activity reported in the pharmaceutical preparation manufacturing market included actions for PHLOW CORP., BAVARIAN NORDIC A/S, and EMERGENT BIOSOLUTIONS CANADA INC during the 12 months through September 10, 2026.

Action obligations are transaction-level amounts, not current award-level obligations.

Which procurement methods were reported for HHS contracts under NAICS 325412?

From September 11, 2025 through September 10, 2026, HHS reported 107 positive-obligation awards for pharmaceutical preparation manufacturing under NAICS 325412. The leading award type was definitive contract. The leading reported procedure was only one source.

Positive-obligation awards
107
Leading reported procedure
Only One Source
26.3% of positive obligations
Leading award type
Definitive Contract
67.4% of positive obligations
Full and open
37%
of positive obligations
Reported parent IDV
32.1%
of positive obligations
Observed vehicles
VA FSS Schedule 65IB
Exact matches from reported parent PIIDs

Percentages use positive obligations as the denominator.

Which HHS pharmaceutical preparation manufacturing awards may warrant recompete research?

6 HHS pharmaceutical preparation manufacturing awards may warrant recompete research based on reported potential-end dates, including awards held by BAVARIAN NORDIC A/S, PARTNER THERAPEUTICS, INC., and ALVOGEN, INC.

Research leads, not confirmed recompetes. Dates may change through later modifications.

Apply this research to a live pursuit

Sweetspot connects opportunity qualification, competitive research, capture, and proposal work in one workspace.

See Sweetspot in action

Related market research

Complete market indexes:

Same NAICS at other agencies:

Nearby NAICS at this agency:

Markets sharing leading prime records:

Reported obligations include contract actions from October 1, 2021 through September 10, 2026. Set-aside and business-size fields reflect award records, not a contractor's current eligibility.

Review data methodology